Spruce Biosciences Inc (SPRB NASDAQ) stock market data APIs
$0.3525
0.02(6.1%)
as of March 13, 2025
Spruce Biosciences Inc Financial Data Overview
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Prev. Close
0.328
Open
0.3525
High
0.3525
Low
0.324
52 wk Range
0.323-0.87
Market Cap
13 626 K
Shares Outstanding
41 303 K
Revenue
7 101 K
Beta
2.344
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Spruce Biosciences Inc data using free add-ons & libraries
Get Spruce Biosciences Inc Fundamental Data
{
"General": {
"Code": "SPRB",
"Type": "Common Stock",
"Name": "Spruce Biosciences\u00a0Inc",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG00HYZ1522",
"ISIN": null,
"CUSIP": null,
"CIK": "0001683553",
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": "2020-10-09",
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": null,
"IsDelisted": false,
"Description": "Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from cong..."
}
}Spruce Biosciences Inc Fundamental data includes:
- Net Revenue: 7 101 K
- EBITDA: -43 188 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spruce Biosciences Inc News
New
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences, Inc. (SPRB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -...
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
SOUTH SAN FRANCISCO, Calif., June 12, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies f...
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif., May 25, 2023--(BUSINESS WIRE)--Spruc...
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 24, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies fo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
